HIV prevention drug hailed as breakthrough, but who gets access?

Widespread licensing agreements, tiered pricing, or public-private partnerships that expand access could reduce reputational and regulatory risk for the manufacturer, potentially stabilizing long-term market positioning and reducing pressure from advocacy groups or government intervention.

If access remains concentrated in high-income markets with limited expansion to lower-income regions, the drug's commercial trajectory would likely follow standard pharmaceutical patterns—strong revenue in developed markets offset by persistent criticism, with minimal near-term pressure on the company's valuation or market share.

Sustained advocacy campaigns, compulsory licensing threats, or regulatory action in major markets over equity concerns could impose compliance costs, supply-chain fragmentation, or brand damage that would weigh on investor confidence and the drug's long-term commercial viability.